Stem cell factory opens door for trials of personalized diabetes treatment
By Andrew Joseph,
Stat News
| 06. 16. 2016
In a step that could lead to a new diabetes treatment, several Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and biotech Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.
It is one of several initiatives around the country aimed at manufacturing cell-derived treatments, as the hope for such therapies creates a demand for the production of the cells.
In patients with type 1 diabetes, the immune system attacks the pancreatic cells that produce insulin, called beta cells. Doctors have for years transplanted beta cells from dead donors into patients, but the supply is insufficient for the millions of people with type 1 diabetes, and patients’ bodies sometimes reject the donor cells.
Continue reading on STAT News
Image via Wikimedia
Related Articles
By Anna Louie Sussman, The New York Times | 07.01.2026
Birthrates in much of the developed world are at record lows, but there’s one demographic group that’s exploring new frontiers of fertility: ultrawealthy men. Deploying nearly limitless resources, a small number of them are reproducing at such an extraordinary scale...
By Anna Rogers, Mother Jones | 06.19.2026
By Daniela J. Lamas, The New York Times | 06.22.2026
In the first hours after my daughter was born, three years ago now, I searched her for answers. I examined her ears, looking for the telltale shape associated with certain genetic syndromes. I inspected her mouth for a cleft palate...
By Julia Métraux, Mother Jones | 06.16.2026
"Robert F. Kennedy Jr." by Gage Skidmore via Wikimedia Commons licensed under CC by SA 3.0
On Tuesday, the Trump administration announced that it would move two key functions of the Department of Education—disability education oversight and the department’s...
